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Abstract Dioxins invade the body mainly through the diet, and
produce toxicity through the transformation of aryl hydrocarbon
receptor (AhR). An inhibitor of the transformation should
therefore protect against the toxicity and ideally be part of the
diet. We examined flavonoids ubiquitously expressed in plant
foods as one of the best candidates, and found that the subclasses
flavones and flavonols suppressed antagonistically the transfor-
mation of AhR induced by 1 nM of 2,3,7,8-tetrachlorodibenzo-p-
dioxin, without exhibiting agonistic effects that transform AhR.
The antagonistic IC50 values ranged from 0.14 to 10 WM, close to
the physiological levels in human. ß 2000 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
Dietary exposure to the environmental pollutants dioxins is
a serious health concern. Dioxins transform the cytosolic aryl
hydrocarbon receptor (AhR), resulting in its translocation
into the nucleus and interaction with a speci¢c DNA element
known as the dioxin-responsible element (DRE) [1,2]. Subse-
quently, this induces the gene expression of several carcino-
genesis-related enzymes, and is associated with teratogenesis,
tumor promotion, immunotoxicity and epithelial hyperplasia
[3^6]. As the transformation of AhR is a primary and key step
in the development of dioxin toxicity, an inhibitor of the
transformation would protect against the toxicity. The inhib-
itors should ideally be factors in our daily diet, because diox-
ins enter the body mainly through the diet. However, the only
inhibitors identi¢ed to date are synthetic drugs [7^9].
AhR has been found to favor compounds that are hydro-
phobic and have van der Waals dimensions of 14U12U5 Aî
[1,2,8]. Flavonoids have these chemical characteristics, and are
abundant in plant foods [10,11]. The subclasses £avones and
£avonols are usually ingested from vegetables, fruits, teas and
red wine, and £avanones, iso£avones and catechins from cit-
rus fruits, beans and teas, respectively [12,13]. The daily intake
is estimated to be 23 mg per capita in The Netherlands, 170
mg in the USA and 70 mg in Japan [14]. In addition, recent
information suggests that several £avonoids act as inhibitors
[15]. Therefore, we considered the £avonoid a good dietary
candidate for preventing dioxin toxicity. The purpose of this
study was to investigate the inhibitory IC50 values of £avo-
noids for the transformation of AhR induced by 1 nM of
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), and thereby to
understand which £avonoids are available as inhibitors by
comparing their IC50 values to the physiological levels.
2. Materials and methods
2.1. Materials
The £avonoids apigenin and hesperetin were obtained from Sigma
(St. Louis, MO). Baicalein, daidzein, eriodictyol, galangin, isorham-
netin, kaempferol, luteolin, luteolin-7,3P-O-bis-glucoside, tamarixetin,
and tangeretin were from Extrasynthe'se (Genay, France). Chrysin and
myricetin were from Aldrich (Tokyo, Japan). Fisetin, £avanone, gen-
istein, quercetin, and rutin were from Wako Pure Chemical (Tokyo,
Japan). Flavone, morin, naringenin, and quercitrin were from Nacalai
Tesque (Kyoto, Japan). Flavonol and naringin were from Tokyo Ka-
sei Kogyo (Tokyo, Japan). Puerarin was from Funakoshi (Tokyo,
Japan). The catechins (+)-catechin, (3)-gallocatechin, (3)-catechin
gallate, (3)-gallocatechin gallate, (3)-epicatechin, (3)-epigallocate-
chin, (3)-epicatechin gallate, and (3)-epigallocatechin gallate were
purchased from Kurita Kogyo (Tokyo, Japan). The purity of each
chemical was con¢rmed by a nuclear magnetic resonance spectral
analysis with a Bruker AC-250 (Bruker Analytik GmbH). K-Naph-
tho£avone, L-naphtho£avone and 4,7-phenanthroline were from Al-
drich. Ellipticine was obtained from Sigma. TCDD and 20-methyl-
cholanthrene (MC) were purchased from Accu Standard (New Haven,
CT, USA) and Nacalai Tesque, respectively. All other reagents used
were of the highest grade available from commercial source.
2.2. Preparation of rat hepatic cytosol
Rat hepatic cytosol was used as a source of AhR to determine the
transformation in a cell-free system. Livers from male Sprague^Daw-
ley rats (6 weeks old, 140^170 g) (Japan SLC; Shizuoka, Japan) were
perfused with ice-cold phosphate-bu¡ered saline and homogenized in
a double volume of HEDG bu¡er (25 mM HEPES pH 7.4, 1.5 mM
EDTA, 1.0 mM dithiothreitol, 10% glycerol). The homogenate was
centrifuged at 105 000Ug for 70 min, and the supernatant was re-
ferred to as cytosol.
2.3. Evaluation of the AhR transformation
The cytosol (4.0 mg protein/ml) was incubated with TCDD or MC
in dimethylsulfoxide (DMSO) in HEDG bu¡er at 20‡C for 2 h, and
with DMSO (10 Wl/ml) alone as a control. In the antagonism test,
£avonoid or catechin at various concentrations was added to the
mixture 10 min prior to the incubation.
Transformation of AhR in the cytosol was evaluated by a gel mo-
bility shift assay [16], using a prepared oligonucleotide for DRE. The
DRE probe corresponded to the 26-bp AhR binding site [3]: 5P-GAT
CTG GCT CTT CTC ACG CAA CTC CG-3P (coding) and 5P-GAT
CCG GAG TTG CGT GAG AAG AGC CA-3P (non-coding). The
prepared double-strand oligonucleotide was 5P-end labeled with T4-
polynucleotide kinase (Takara Biomedicals, Kusatsu, Japan) and [Q-
32P]ATP. The reaction mixture for the binding of AhR/DRE consisted
of 20 Wg of cytosolic protein, 200 ng of poly[dI-dC] (Boehringer
Mannheim GmbH, Germany) and 32P-labeled DRE probes (100
kcpm, 20 fmol) in a ¢nal volume of 25 Wl of HEDG bu¡er containing
150 mM KCl. The mixture was loaded on 4% non-stacking native
polyacrylamide gels containing TAE bu¡er (6.7 mM Tris^HCl, pH
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7.5, 3.3 mM sodium acetate, 1 mM EDTA), and electrophoresed in
the same bu¡er at 135 V for 30 min before loading and for 150 min
after loading. The AhR/DRE complex was identi¢ed by competition
assay with a 50-fold excess of non-labeled DRE probe and determined
by autoradiography with a Digital Imaging System Is-1000 (Alpha
Innotech).
3. Results
3.1. Antagonism of £avonoid on AhR transformation
On incubating AhR with 1 nM TCDD, e¡ects of £avonoid
on the complex of AhR/DRE were determined by gel mobility
shift assay. Fig. 1A shows that additions of £avonoid prior to
TCDD suppressed the formation of the AhR/DRE complex
while additions after AhR had been transformed by TCDD
were ine¡ective against the suppression. Thus, £avonoids in-
hibited the transformation of AhR competing with the agonist
TCDD, i.e. antagonistically. Fig. 1B,C shows typical results
for the antagonistic action of £avonoid. Quercetin suppressed
TCDD-induced transformation dose-dependently (Fig. 1B).
Luteolin similarly suppressed the transformation induced by
5 nM of MC (Fig. 1C), which is another strong agonist [17].
3.2. Antagonistic IC50 and agonistic ED50 values of £avonoids
We determined the IC50 values by plotting a log of the dose
concentration against the ratio of transformation. As shown
in Fig. 2, using both a positive control (1 nM TCDD, 100%)
and a negative one (vehicle alone, 0%) at each time, the sup-
pressing activity of £avonoid was plotted as % of transforma-
tion from independent triplicate assays. On the other hand,
some £avonoids have been reported to exhibit agonistic action
and produce toxicity [15,18]. Therefore, we also determined
the agonistic ED50 values.
Table 1 lists the IC50 values for 34 natural £avonoids and
four known antagonistic drugs, along with the agonistic ef-
fects for comparison. Almost all of the natural £avonoids
showed antagonism without agonism. Flavone and tamarixe-
tin had agonistic e¡ects, but the ED50 values were higher by
one or two orders of magnitude than the corresponding an-
tagonistic IC50 values. Chrysin, £avonol, quercetin, £avanone,
and daidzein at 100 WM had a weak agonistic e¡ect. This
means that natural £avonoids at low concentrations inhibit
the dioxin action and are not in themselves toxic.
Fig. 1. Inhibitory e¡ect of £avonoids on TCDD- or MC-induced
transformation of AhR. A: A typical gel retardation assay for the
e¡ect of £avones and £avonols. Arrows indicate AhR/DRE com-
plex. Rat hepatic cytosol was incubated with 5 WM £avonoids be-
fore (pre-treatment, lanes 3^6) or after (post-treatment, lanes 7^10)
the transformation of AhR by 1 nM TCDD. Lane 1, the vehicle
DMSO alone; 2, 1 nM TCDD alone; 3 and 8, £avone; 4 and 9,
chrysin; 5 and 10, £avonol; 6 and 11, galangin; 7 and 12, £ava-
none. B: Dose-dependent e¡ect of £avonoids on transformation.
Quercetin was added to the cytosol at a concentration of 0^20 WM
before the treatment with 1 nM TCDD. C: Inhibitory e¡ect of £a-
vonoids on the MC-induced system. Luteolin was added to the cy-
tosol at 0^50 WM before treatment with 5 nM MC.
Fig. 2. Determination of IC50 values of £avonoids for suppressing
the AhR transformation. Rat hepatic cytosol was incubated with
various concentrations of £avonoids: tangeretin (A), galangin (B),
eriodictyol (C), and rutin (D), before being treated with 1 nM
TCDD, and the transformation of AhR was determined as men-
tioned in Fig. 1. The ratio of transformation was compared to those
of both a positive control (1 nM TCDD) and a negative one (ve-
hicle alone) and plotted as % of transformation against a log of the
dose concentration. The determination was carried out three times
independently, and then the amount requiring 50% suppression was
calculated.
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3.3. Relation between the structure and the antagonistic activity
In antagonistic action, £avones, £avonols and £avanones
showed low IC50 values, and non-polar or less polar molecules
were stronger. Subsequently, £avone, £avonol, galangin, and
£avanone gave values similar to that of a known antagonistic
drug, K-naphtho£avone. The results indicated that hydropho-
bicity and molecular size were important for AhR. AhR also
favors a stereo coplanar structure like the strongest agonist
Table 1
E¡ects of £avonoids on the transformation of AhRa
Chemical (position of substituent) Antagonistic IC50 (WM) against Agonistic ED50 (WM or maximum
% when added at 100 WM)b
1 nM TCDD 5 nM MC
Flavones
Flavone (none) 0.14 0.62 23
Chrysin (5,7-OH) 4.2 3.8 weak (32 þ 6)
Baicalein (5,6,7-OH) 4.3 5.3 no e¡ect
Apigenin (5,7,4P-OH) 3.2 7.1 no e¡ect
Luteolin (5,7,3P,4P-OH) 6.5 8.4 no e¡ect
Tangeretin (5,6,7,8,3P-OCH3) 9.0 8.2 no e¡ect
Luteolin-7,3P-O-bis-glucoside 28 ^ no e¡ect
Flavonols
Flavonol (3-OH) 0.42 1.2 weak (33 þ 3)
Galangin (3,5,7-OH) 0.22 1.3 no e¡ect
Kaempferol (3,5,7,4P-OH) 2.1 9.0 no e¡ect
Fisetin (3,7,3P4P-OH) 5.5 ^ no e¡ect
Morin (3,5,7,2P,4P-OH) 7.4 s 50 no e¡ect
Quercetin (3,5,7,3P,4P-OH) 1.5 10 weak (15 þ 2)
Myricetin (3,5,7,3P,4P,5P-OH) 7.6 ^ no e¡ect
Tamarixetin (3,5,7,3P-OH, 4P-OCH3) 2.4 ^ 89
Isorhamnetin (3,5,7,4P-OH, 3P- OCH3) 10 ^ no e¡ect
Quercetin-3-O-rhamnoside (quercitrin) 3.7 35 no e¡ect
Quercetin-3-O-rutinoside (rutin) 13 s 50 no e¡ect
Flavanones (2^3 is saturated)
Flavanone (none) 0.65 ^ weak (12 þ 2)
Naringenin (5,7,4P-OH) 6.7 ^ no e¡ect
Eriodictyol (5,7,3P,4P-OH) 11 ^ no e¡ect
Hesperetin (5,7,3P-OH, 4P-OCH3) 14 ^ no e¡ect
Naringenin-7-O-rutinoside (naringin) 25 ^ no e¡ect
Iso£avones (B-ring binds to 3-position)
Daidzein (7,4P-OH) s 50 s 50 weak (34 þ 1)
Genistein (5,7,4P-OH) s 50 s 50 no e¡ect
Daidzein-8-glucoside (puerarin) s 50 ^ no e¡ect
Catechins
(+)-Catechin (R1 = H, R2 = H, R3 = OH) s 200 ^ no e¡ect
(3)-Gallocatechin (R1 = OH, R2 = H, R3 = OH) s 200 ^ no e¡ect
(3)-Catechin gallate (R1 = H, R2 = H, R3 = OG) 150 ^ no e¡ect
(3)-Gallocatechin gallate (R1 = OH, R2 = H, R3 = OG) 39 ^ no e¡ect
(3)-Epicatechin (R1 = H, R2 = OH, R3 = H) s 200 ^ no e¡ect
(3)-Epigallocatechin (R1 = OH R2 = OH, R3 = H) s 200 ^ no e¡ect
(3)-Epicatechin gallate (R1 = H, R2 = OG, R3 = H) 81 ^ no e¡ect
(3)-Epigallocatechin gallate (R1 = OH, R2 = OG, R3 = H) 35 ^ no e¡ect
Known antagonistic and agonistic drugs
7,8-Benzo£avone (K-naphtho£avone) 0.39 ^ 31
5,6-Benzo£avone (L-naphtho£avone) no e¡ect ^ 2.7
4,7-Phenanthroline 6.8 ^ no e¡ect
5,11-Dimethyl-6H-pyrido[3,4-b]carbazole (ellipticine) 0.013 ^ no e¡ect
aThe amounts of AhR/DRE complex were determined as a percentage of control incubation without £avonoids, and plotted vs. £avonoid con-
centrations to calculate the IC50 values.
b‘No e¡ect’ is up to 100 WM.
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TCDD [1,2,18]. Flavones and £avonols have a plane benzo-
pyranone skeleton, and £avanones a less plane dihydrobenzo-
pyranone skeleton, but catechins are not plane benzodihydro-
pyrans. Subsequently, in antagonistic action the £avonoids
ranked in the order of £avones and £avonolss flavano-
ness catechins. Iso£avones having almost no e¡ect di¡ered
markedly in stereo structure from the above £avonoids in
that the B-ring was bound to the 3-position.
Luteolin-7, 3P-O-bis-glucoside, naringenin-7-O-rutinoside
and isorhamnetin were weaker than the corresponding agly-
cones (skeleton without sugar), though a 3-substitute such as
quercetin-3-O-rhamnoside was not. These results reveal a re-
gion of the £avonoid with a⁄nity for the hydrophobic pocket
of AhR comprising 7- and 8-carbons, 1-pyran and a B-ring,
and this was consistent with a ¢nding for a cytochrome P450
(CYP) 1A1 [19]. CYP 1A1 is one of the enzymes that are
expressed through AhR and metabolize hydrophobic xenobi-
otics [3^5]. The similarity between the hydrophobic pockets of
AhR and CYP is purposive.
3.4. Changes in the IC50 values with TCDD level
The dioxin level in the body is usually much less that the
1 nM in Table 1 [1,2]. Therefore, we determined the changes
in the IC50 values with TCDD concentration in several £avo-
noids (Table 2). This, together with the results at 1 nM
TCDD in Table 1, indicated that the antagonistic action of
£avones and £avonols depended on the concentration of ago-
nistic TCDD. Thus, £avonoid was available at lower levels
against a smaller amount of TCDD.
4. Discussion
The present study demonstrates that £avonoids, especially
£avones and £avonols in aglycones, inhibit the AhR trans-
formation antagonistically, indicating that they protect
against dioxin toxicity. Therefore, an important question is
whether £avonoids are present in the body at antagonistic
levels and reach agonistic levels. The physiological concentra-
tions of dietary £avonoids have been established by several
excellent studies.
In absorption experiments in volunteers, onion quercetin,
pure rutin and pure aglycone quercetin have been reported to
be absorbed into the body at 52, 17 and 24% of the intake
amount, respectively [20,21]. The levels in healthy individuals
are 0.72^0.76 WM for rutin and 0.5^1.6 WM for other querce-
tin glycosides in the blood plasma [22]. Hollman and cowork-
ers have examined the changes in physiological levels with a
single dose of £avonoid after washing out the internal £avo-
noid [20,21]. Fried onion equivalent to 68 mg (225 Wmol)
quercetin gives 0.74 WM in plasma as a peak at 0.7^7 h after
the ingestion, and pure rutin 0.3 WM. The disposition has an
elimination half-life of about 25 h. The authors concluded
that the levels re£ect the amount ingested and that repeated
intake of quercetin throughout the day would lead to a build-
up in the plasma. Indeed, in another experiment by Conquer
et al. [23], a capsule containing free quercetin raised the con-
centration to 1.5 WM after 28 days at a dose of 1 g/day.
Quercetin and its glycosides bind to albumin and are carried
in the blood stream to the liver, where they are partly metab-
olized to isorhamnetin and glucurono-sulfated conjugates be-
fore being excreted in the urine [24,25]. The other £avonoids
have a similar fate. Kaempferol is absorbed better or metab-
olized to a lesser extent than quercetin [21]. A daily supple-
ment of 500 g of broccoli (providing 12.5 mg of kaempferol
and 9 mg of quercetin) for 12 days resulted in small amounts
in the urine as conjugates of the non-metabolized aglycone
(52^78 ng kaempferol/ml urine) [26]. An oral dose of 500
mg of pure naringin gives naringin, naringenin and naringenin
glucuronides in the urine [27]. A capsule of 525 mg of epigal-
locatechin gallate (roughly equivalent to six cups of green tea)
increases the plasma levels to 4.41 WM after 90 min as the free
form but not the conjugates [28].
Thus, aglycones and glycosides from the diet are excreted
into urine as free aglycones and conjugates thereof. Since the
conjugations occur in the intestines and liver [24,25], the diet-
ary £avonoids exist as free aglycones at least temporarily in
these tissues, which are major routes for dietary dioxins [1,2].
The physiological levels indicate that the dietary £avones and
£avonols can build up to near antagonistic levels and on re-
peated ingestion reach close to the IC50 value, i.e. 1.5 WM for
quercetin (Table 1), but do not approach agonistic levels such
as 100 WM for quercetin. In addition, the dioxin level is usu-
ally pM in the body [1,2], much less that the 1 nM in Table 1.
Towards the lower concentration of TCDD, £avones and £a-
vonols acted as antagonists at lower concentrations (Table 2).
Probably, the intake from a plant-based diet is enough to
inhibit AhR transformation by TCDD. The present results
obtained from experiments in a cell-free system suggest
strongly that the dietary £avones and £avonols protect against
the toxicity of the environmental contaminant dioxin, because
the transformation of AhR has been recognized to be a pri-
mary and key step in the development of dioxin toxicity [3^6].
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